ATE557094T1 - Krebsspezifische promotoren - Google Patents

Krebsspezifische promotoren

Info

Publication number
ATE557094T1
ATE557094T1 AT05767457T AT05767457T ATE557094T1 AT E557094 T1 ATE557094 T1 AT E557094T1 AT 05767457 T AT05767457 T AT 05767457T AT 05767457 T AT05767457 T AT 05767457T AT E557094 T1 ATE557094 T1 AT E557094T1
Authority
AT
Austria
Prior art keywords
cancer
specific
control sequences
specific control
combination
Prior art date
Application number
AT05767457T
Other languages
English (en)
Inventor
Mien-Chie Hung
Chi-Ping Day
Kun-Ming Rau
Xiaoming Xie
Zheng Li
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE557094T1 publication Critical patent/ATE557094T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05767457T 2004-04-02 2005-04-01 Krebsspezifische promotoren ATE557094T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55911104P 2004-04-02 2004-04-02
PCT/US2005/011067 WO2005103251A2 (en) 2004-04-02 2005-04-01 Cancer specific promoters

Publications (1)

Publication Number Publication Date
ATE557094T1 true ATE557094T1 (de) 2012-05-15

Family

ID=35057078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05767457T ATE557094T1 (de) 2004-04-02 2005-04-01 Krebsspezifische promotoren

Country Status (9)

Country Link
US (2) US7816131B2 (de)
EP (1) EP1737966B1 (de)
JP (1) JP2007535315A (de)
CN (1) CN1997745A (de)
AT (1) ATE557094T1 (de)
DK (1) DK1737966T3 (de)
ES (1) ES2385492T3 (de)
PT (1) PT1737966E (de)
WO (1) WO2005103251A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US7709253B2 (en) * 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
US20090192101A1 (en) * 2006-11-22 2009-07-30 Mien-Chie Hung Cancer-specific promoters
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
CN102056622B (zh) 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
WO2010097419A1 (en) 2009-02-25 2010-09-02 Fundació Privada Centre De Regulació Genòmica (Crg) Conditionally replicating adenovirus effective in the treatment of tumors
JP5733705B2 (ja) * 2009-03-30 2015-06-10 国立大学法人 岡山大学 特異的プロモーターの活性を上昇させるシステム及び該システムを保持したベクター
JP5963363B2 (ja) * 2010-09-30 2016-08-03 国立大学法人 鹿児島大学 Ａｕｒｏｒａキナーゼプロモーターを含む増殖制御型ウイルスベクター
CN103502459B (zh) * 2010-12-24 2016-04-13 新加坡科技研究局 抗基因沉默的经修饰的人cmv启动子
CN102352369A (zh) * 2011-07-06 2012-02-15 中山大学肿瘤防治中心 一种在肿瘤细胞中高效高特异表达靶基因的载体t-visa
CN102327624A (zh) * 2011-09-28 2012-01-25 中山大学肿瘤防治中心 一种可高效在体内外转染基因的新型脂质体及其制备方法
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
CN102716498A (zh) * 2012-03-12 2012-10-10 中山大学肿瘤防治中心 一种可高效高特异灭杀p53基因突变型乳腺癌细胞的药物脂质体
EP3004357A4 (de) 2013-06-04 2017-01-11 The Johns Hopkins University Peg-prom-vermittelte oberflächenexpression von avidin/streptavidin
WO2014197535A1 (en) 2013-06-04 2014-12-11 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
WO2014209553A1 (en) 2013-06-04 2014-12-31 Virginia Commonwealth University Use of a truncated ccn1 promoter for cancer diagnostics, therapeutics and theranostics
EP3004872B1 (de) 2013-06-04 2017-10-18 Virginia Commonwealth University Mda-9/syntenin-promotor zur abbildung und behandlung metastatischer krebszellen
EP3003393A4 (de) 2013-06-04 2017-01-11 The Johns Hopkins University Dreiteilige theranostische krebs-nukleinsäurekonstrukte
US10412939B2 (en) * 2015-09-02 2019-09-17 Regeneron Pharmaceuticals, Inc. Rodent model of prostate cancer
JOP20190166A1 (ar) * 2017-01-05 2019-07-02 Univ Texas استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
US12233135B2 (en) 2018-04-11 2025-02-25 Precision Molecular Inc. Therapeutic constructs for treating cancer
US20230038502A1 (en) 2019-06-11 2023-02-09 Shire Human Genetic Therapies, Inc. Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
EP4048800A1 (de) 2019-10-23 2022-08-31 Shire Human Genetic Therapies, Inc. Auf adeno-assoziierten virusvektoren basierende gentherapie für hereditäres angioödem
US20220186252A1 (en) 2020-12-16 2022-06-16 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
AU5742198A (en) 1997-02-03 1998-08-25 Commonwealth Scientific And Industrial Research Organisation Tissue specific promoters
AUPO492397A0 (en) 1997-02-03 1997-02-27 Commonwealth Scientific And Industrial Research Organisation Prostate specific promoters
GB9703633D0 (en) * 1997-02-21 1997-04-09 Imp Cancer Res Tech Cancer therapy
AU9402898A (en) 1997-09-26 1999-04-23 Washington University Cell death agonists
WO2000026343A2 (en) 1998-10-30 2000-05-11 Case Western Reserve University Tissue specific promoters and transgenic animals for the screening of pharmaceuticals
US6716824B1 (en) * 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
JP2001218587A (ja) 2000-02-08 2001-08-14 Academia Sinica 最小ｃｍｖプロモーターを含むバキュロウイルス
US6838556B2 (en) * 2000-06-06 2005-01-04 Genelabs Technologies, Inc. Promoters for regulated gene expression
EP1207204A1 (de) 2000-11-16 2002-05-22 KWS Saat AG Gewebespezifische Promotoren aus der Zuckerrübe
DE10209451A1 (de) * 2002-03-05 2003-09-18 Universitaetsklinikum Hamburg Spezifische Genexpression in Kolonkarzinom-Zell-Linien
US20050118154A1 (en) * 2003-04-02 2005-06-02 Mien-Chie Hung Antitumor effect of mutant Bik

Also Published As

Publication number Publication date
WO2005103251A3 (en) 2006-04-27
US20050260643A1 (en) 2005-11-24
WO2005103251A2 (en) 2005-11-03
US7723104B2 (en) 2010-05-25
EP1737966B1 (de) 2012-05-09
US7816131B2 (en) 2010-10-19
DK1737966T3 (da) 2012-07-09
CN1997745A (zh) 2007-07-11
ES2385492T3 (es) 2012-07-25
US20080286860A1 (en) 2008-11-20
EP1737966A2 (de) 2007-01-03
JP2007535315A (ja) 2007-12-06
PT1737966E (pt) 2012-08-06

Similar Documents

Publication Publication Date Title
DK1737966T3 (da) Cancerspecifik promotorer
IL243812A0 (en) Compounds of diarylhydantoin
Stock et al. Gene deregulation in gastric cancer
MX2010003658A (es) Sistema quirurgico no invasivo basado en fotones que incluye control celular automatico y erradicacacion por control de proalimentacion pre-calculada mas control de retroalimentacion de imagen para suministro enfocado de energia.
SG170809A1 (en) Diarylthiohydantoin compounds
MY183404A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
BR112013029212A2 (pt) anticorpos para o tratamento de câncer expressando claudina-6
ZA202106392B (en) Therapeutic rna for prostate cancer
TN2012000188A1 (en) Novel antitumoral use of cabazitaxel
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
Haase-Kohn et al. Metastatic potential of B16-F10 melanoma cells is enhanced by extracellular S100A4 derived from RAW264. 7 macrophages
IN2012DN05143A (de)
WO2010054397A3 (en) N-cadherin: target for cancer diagnosis and therapy
WO2008070448A3 (en) Cancer-specific promoters
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
WO2009126315A3 (en) Macrocyclic compounds and methods of treatment
MX2021012931A (es) Polipeptidos multiespecificos activables y terapeuticos con semivida extendida.
EA201200190A1 (ru) Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы
WO2009038771A3 (en) Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
WO2008144659A3 (en) Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers
ATE552887T1 (de) Tumorspezifischer vektor für die gentherapie
GB202205161D0 (en) Nucleotide delivery of cancer therapy